ES2189165T3 - Nuevos compuestos macrociclicos como inhibidores de metaloproteasa. - Google Patents
Nuevos compuestos macrociclicos como inhibidores de metaloproteasa.Info
- Publication number
- ES2189165T3 ES2189165T3 ES98921183T ES98921183T ES2189165T3 ES 2189165 T3 ES2189165 T3 ES 2189165T3 ES 98921183 T ES98921183 T ES 98921183T ES 98921183 T ES98921183 T ES 98921183T ES 2189165 T3 ES2189165 T3 ES 2189165T3
- Authority
- ES
- Spain
- Prior art keywords
- compounds
- inhibitors
- metaloproteasa
- macrociclic
- new
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Un compuesto, y una de sus formas de sal farmacéuticamente aceptable, seleccionado de: 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[glicina - n - pentil éster] - ciclopentadecano - 13 - N - hidroxi - carboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[N - 4 - fenil - 1 - butilamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[5 - metoxitriptamina] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[1 - (2, 5 - dimetoxifenil) - 2 - glicina - amidoetanol] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[glicina - t - butil éster] - ciclopentadecano - 13 - N - hidroxi - carboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[ácido L - glutámico - a, g - di - t - butil éster] -ciclopenta - decano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[glicina] - ciclopentadecano - 13 N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[N - 2 - fenil - 1 - butilamida] - ciclopentadecano - 13 - N - hidroxicarboxamida 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[2 - (2 - aminoetil) - 1 - metilpirrol] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[2 - (2 - aminoetil)bencenosulfonamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[L - ácido glutámico - g - ciclohexil éster - N - metil amida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[L - fenilalanina - p - fluoro - N metilamida] - ciclopentadecano - 13 - N - hidrixicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[L - fenilalanina - p - metoxi - N (S) - a - metilbencilamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[N - ciclohexilmetil amida] - ciclopentadecano - 13 - N - hidroxi - carboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[N - 3 - fenil - 1 - propil - amida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[N - 3, 3 - difenilpropil amida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[N - (2 - aminoetilamino)etil pirrolidina] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[L - 3(2¿ - nafti1)alanina - N - metil amida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[etil - 4 - amino - 1 - piperidina carboxilato] - ciclopentade cano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[5 - metil - triptamina] - ciclopentadecano - 13 - N - hidroxi - carboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[N - 4 - trifluorometilbencil amida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[L - ácido glutámico] - ciclopentadecano - 13 - N - hidroxi - carboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[2 - (dietilamino)etil - 4 - amino benzoato] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[6 - fluorotriptamina] - ciclopentadecano - 13 - N - hidroxi - carboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 -isobutil - 2[6 - metoxi triptamina] - ciclopentadecano - 13 - N - hidroxi - carboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2[triptamina] - ciclopentadecano 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (glicina - N - 4 - metilpiperazinamida)carboxamida] - ciclo - pentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (L - alanina - N - morfolinamida)carboxamida] - ciclopenta - decano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (L - valina - N - morfolinamida)carboxamida] - ciclopenta - decano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (L - terc - butilglicina - N morfolinamida)carboxamida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (b - alanina - N - morfolinamida)carboxamida] - ciclopenta - decano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (etoxicarbonil - N - morfolinamida)carboxamida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (2 - hidroxi - 2 - feniletil)carboxamida]ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 3S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (glicina - N - 4 - bencilpiperazinamida)carboxamida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (glicina - N - 4 - fenilpiperazinamida)carboxamida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (glicina - N - 4 - (2 - piridil)piperazinamida)carboxamida] ciclopentadecano - 13 - N -hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (a - ciclopropanoetiloxicarboxamida - b - alanina) - carboxamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - {N - [glicina - N - 4 - (1 - piperidinil)piperidinamida] - carboxamida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (R - isopropiloxicarbonil N - morfolinamida)carboxamida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (S - isopropiloxicarbonil N - morfolinamida)carboxamida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (2 - tiazol - 4 - ácido acético)carboxamida]ciclopenta - decano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo- 9 - oxa - 14 - isobutil - 2 - [N - (a - ciclopropanoetiloxicarboxamida - b - alanina - N - dimetilamida)carboxamida]ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (a - ciclopropanoetiloxicarboxamida - b - alanina - N - morfolinamida)carboxamida]ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (2 - tiazol - 4 - acetil - N morfolinamida)carboxamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (L - serina - N - morfolinamida)carboxamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (glicina - N - piperidinamida - 3 - ácido carboxílico) - carboxamida]ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (glicina - N - 2, 6 - dimetilmorfolinamida)carboxamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (glicina - N - 4 - etoxicarbonilpiperazinamida) - carboxamida]ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (glicina - N - 4 - etoxicarbonilpiperidinamida) carboxamida]ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - {N - [4 - (1 morfolinil)fenil]carboxamida}ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - {N - [glicina - N - (4 - (1 - morfolinil)anilida)carboxamida] ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - (glicina - N - piperidinamida - 4 - ácido carboxílico) - carboxamida] -ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [N - metilcarboxamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [alanina - N - metilamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [metilcarboxi] - ciclopentadecano 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [glicina - N - metilamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [2 - N - morfolinoetilcarboxamida] - ciclopentadecano - 13 - N - hidroxicarboxamida; 2S, 13S, 14R - 1, 7 - diaza - 8, 15 - dioxo - 9 - oxa - 14 - isobutil - 2 - [3 - N - morfolinopropilcarboxamida] - ciclopentadecano - 13 - N - hidroxicarbox
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/856,223 US6281352B1 (en) | 1995-11-14 | 1997-05-14 | Macrocyclic compounds as metalloprotease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2189165T3 true ES2189165T3 (es) | 2003-07-01 |
Family
ID=25323094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES98921183T Expired - Lifetime ES2189165T3 (es) | 1997-05-14 | 1998-05-14 | Nuevos compuestos macrociclicos como inhibidores de metaloproteasa. |
Country Status (9)
Country | Link |
---|---|
US (1) | US6281352B1 (es) |
EP (1) | EP0981521B1 (es) |
JP (1) | JP2001524949A (es) |
AT (1) | ATE229514T1 (es) |
AU (1) | AU7385398A (es) |
CA (1) | CA2287923A1 (es) |
DE (1) | DE69810100T2 (es) |
ES (1) | ES2189165T3 (es) |
WO (1) | WO1998051665A2 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6649377B1 (en) | 1999-05-10 | 2003-11-18 | Syntex (U.S.A.) Llc | Human aggrecanase and nucleic acid compositions encoding the same |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
WO2001092235A1 (en) | 2000-06-01 | 2001-12-06 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
ES2907826T3 (es) | 2001-06-26 | 2022-04-26 | Amgen Inc | Anticuerpos para OPGL |
AU2002238939A1 (en) * | 2002-03-18 | 2003-09-29 | Nihon University | Cyclic etheramine derivatives as medicaments for malignant tumors |
JP4841429B2 (ja) | 2003-04-24 | 2011-12-21 | インサイト・コーポレイション | メタロプロテアーゼの阻害剤としてのアザスピロアルカン誘導体 |
ATE457995T1 (de) | 2003-06-18 | 2010-03-15 | Tranzyme Pharma Inc | Makrozyklische motilin rezeptorantagonisten |
US20090182019A1 (en) * | 2005-04-18 | 2009-07-16 | The Johns Hopkins University | Histone deacetylase inhibitors |
ATE509956T1 (de) * | 2006-06-08 | 2011-06-15 | Helmholtz Zentrum Muenchen | Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie |
AU2008350907A1 (en) | 2007-12-11 | 2009-08-27 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
US11286251B2 (en) * | 2016-04-08 | 2022-03-29 | Yale University | Matrix metalloproteinase inhibitors and imaging agents, and methods using same |
CA3115038A1 (en) | 2018-10-04 | 2020-04-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8827308D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
GB9102635D0 (en) | 1991-02-07 | 1991-03-27 | British Bio Technology | Compounds |
CA2102890A1 (en) | 1991-05-28 | 1992-11-29 | Soumya P. Sahoo | Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents |
US5427954A (en) | 1992-04-29 | 1995-06-27 | Shriner's Hospitals For Crippled Children | Compositions and methods for detection and treatment of human osteoarthritis |
US5318964A (en) | 1992-06-11 | 1994-06-07 | Hoffmann-La Roche Inc. | Hydroxamic derivatives and pharmaceutical compositions |
GB9215665D0 (en) | 1992-07-23 | 1992-09-09 | British Bio Technology | Compounds |
GB9307956D0 (en) | 1993-04-17 | 1993-06-02 | Walls Alan J | Hydroxamic acid derivatives |
GB9320660D0 (en) | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
BR9611563A (pt) | 1995-11-14 | 1999-03-02 | Du Pont Merck Pharma | Composto composição farmacêutica método de tratamento de uma doença inflamatória e ensaio para detectar inibidores de agrecanase |
-
1997
- 1997-05-14 US US08/856,223 patent/US6281352B1/en not_active Expired - Lifetime
-
1998
- 1998-05-14 AU AU73853/98A patent/AU7385398A/en not_active Abandoned
- 1998-05-14 EP EP98921183A patent/EP0981521B1/en not_active Expired - Lifetime
- 1998-05-14 AT AT98921183T patent/ATE229514T1/de not_active IP Right Cessation
- 1998-05-14 ES ES98921183T patent/ES2189165T3/es not_active Expired - Lifetime
- 1998-05-14 DE DE69810100T patent/DE69810100T2/de not_active Expired - Fee Related
- 1998-05-14 CA CA002287923A patent/CA2287923A1/en not_active Abandoned
- 1998-05-14 JP JP53993598A patent/JP2001524949A/ja active Pending
- 1998-05-14 WO PCT/US1998/009789 patent/WO1998051665A2/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP0981521A2 (en) | 2000-03-01 |
US6281352B1 (en) | 2001-08-28 |
JP2001524949A (ja) | 2001-12-04 |
EP0981521B1 (en) | 2002-12-11 |
WO1998051665A3 (en) | 1999-03-25 |
AU7385398A (en) | 1998-12-08 |
ATE229514T1 (de) | 2002-12-15 |
DE69810100D1 (de) | 2003-01-23 |
DE69810100T2 (de) | 2003-11-13 |
CA2287923A1 (en) | 1998-11-19 |
WO1998051665A2 (en) | 1998-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9803851A (es) | Compuestos macrociclicos novedosos como inhibidores de metaloproteasas. | |
WO1999009000A3 (en) | Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis | |
EA200600414A1 (ru) | ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ) | |
EA200501676A1 (ru) | Фосфонатсодержащие ингибиторы киназы (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ ингибирования киназы у млекопитающего (варианты) | |
EA200601212A1 (ru) | Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение | |
DE60029799D1 (de) | Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe | |
ATE444960T1 (de) | Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer | |
DK1309589T3 (da) | Ureaforbindelser og anvendelsesfremgangsmåder | |
ATE329587T1 (de) | Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen | |
BRPI0207961A8 (pt) | Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
NO20055863L (no) | W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer | |
ATE366722T1 (de) | Substituierte pyridin-derivate als entzündungshemmende mittel | |
DK1448564T3 (da) | Substituerede indolizinlignende forbindelser og fremgangsmåder til anvendelse | |
YU64701A (sh) | Jedinjenja upotrebljiva kao anti-inflamatorna sredstva | |
MA27880A1 (fr) | Derives de tetrahydrocarbazole et leur utilisation pharmaceutique | |
DK1315506T3 (da) | Phospholipidderivater af valproinsyre og blandinger deraf | |
ES2189165T3 (es) | Nuevos compuestos macrociclicos como inhibidores de metaloproteasa. | |
EA200500244A1 (ru) | Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии | |
DE60021381D1 (de) | Chinonverbindungen zur behandlung von krankheiten | |
ATE523199T1 (de) | Pyridazinverbindungen und verfahren | |
ATE302002T1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
ES2147973T3 (es) | Estirenos alquilatados como profarmacos de inhibidores de cox-2. | |
ES2182035T3 (es) | Derivados del bisarilciclobuteno como inhibidores de ciclooxigenasa. | |
ATE290857T1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
ATE482217T1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen |